4DMT’s Wet AMD Gene Therapy Results Disappoint Investors, Stock Plummets

1. Stock Performance: 4DMT's stock price fell 32% on Wednesday following the release of Phase II data for its wet AMD gene therapy candidate, 4D-150.
2. Clinical Trial Results: The Phase II PRISM study showed improvements in visual acuity and reduced injection rates, but the data did not meet investor expectations.
3. Safety Profile: The treatment demonstrated a solid safety profile, with no serious adverse events and no significant vitreous inflammation.
4. Future Plans: 4DMT expects additional data readouts from its SPECTRA study in diabetic macular edema in Q4, 2024, and plans to begin a Phase III clinical trial in Q1, 2025.